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Abstract: Background: Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and shows a broad clinical presentation ranging from
asymptomatic infection to fatal disease. A very prominent feature associated with severe COVID-19
is T cell lymphopenia. However, homeostatic and functional properties of T cells are ill-defined in
COVID-19. Methods: We prospectively enrolled individuals with mild and severe COVID-19 into our
multicenter cohort and performed a cross-sectional analysis of phenotypic and functional characteristics
of T cells using 40-parameter mass cytometry, flow cytometry, targeted proteomics, and functional assays.
Results: Compared with mild disease, we observed strong perturbations of peripheral T cell homeostasis
and function in severe COVID-19. Individuals with severe COVID-19 showed T cell lymphopenia and
redistribution of T cell populations, including loss of naïve T cells, skewing toward CD4+ T follicular
helper cells and cytotoxic CD4+ T cells, and expansion of activated and exhausted T cells. Extensive
T cell apoptosis was particularly evident with severe disease and T cell lymphopenia, which in turn
was accompanied by impaired T cell responses to several common viral antigens. Patients with severe
disease showed elevated interleukin-7 and increased T cell proliferation. Furthermore, patients sampled
at late time points after symptom onset had higher T cell counts and improved antiviral T cell responses.
Conclusion: Our study suggests that severe COVID-19 is characterized by extensive T cell dysfunction
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Background: Coronavirus disease 2019 (COVID- 19) is caused by infection with severe 
acute respiratory syndrome coronavirus 2 (SARS- CoV- 2) and shows a broad clinical 
presentation ranging from asymptomatic infection to fatal disease. A very prominent 
feature associated with severe COVID- 19 is T cell lymphopenia. However, homeo-
static and functional properties of T cells are ill- defined in COVID- 19.
Methods: We prospectively enrolled individuals with mild and severe COVID- 19 into 
our multicenter cohort and performed a cross- sectional analysis of phenotypic and 
functional characteristics of T cells using 40- parameter mass cytometry, flow cytom-
etry, targeted proteomics, and functional assays.
Results: Compared with mild disease, we observed strong perturbations of periph-
eral T cell homeostasis and function in severe COVID- 19. Individuals with severe 
COVID- 19 showed T cell lymphopenia and redistribution of T cell populations, includ-
ing loss of naïve T cells, skewing toward CD4+T follicular helper cells and cytotoxic 
CD4+ T cells, and expansion of activated and exhausted T cells. Extensive T cell ap-
optosis was particularly evident with severe disease and T cell lymphopenia, which in 
turn was accompanied by impaired T cell responses to several common viral antigens. 
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1  |  INTRODUC TION
The global epidemic of severe acute respiratory syndrome coronavi-
rus 2 (SARS- CoV- 2), which is the causative agent of coronavirus dis-
ease 2019 (COVID- 19), has resulted in almost 100 million confirmed 
cases and 2 million deaths worldwide as of January 2021. Patients 
with COVID- 19 have a wide spectrum of symptoms ranging from 
asymptomatic infection to severe acute respiratory distress syn-
drome (ARDS).1– 5 Advanced age and comorbidities are risk factors 
for the development of severe disease.6– 8 Furthermore, individuals 
with severe disease have increased amounts and longer duration of 
SARS- CoV- 2 viral shedding in the respiratory mucosa and of viral 
RNA in blood as compared to individuals with mild COVID- 19.9– 12 
Several reports have demonstrated associations between severe 
disease and elevation of systemic inflammatory markers such as C- 
reactive protein (CRP), procalcitonin, and Interleukin- 6 (IL- 6).6,13– 17 
Taken together these data suggest that inefficient adaptive antiviral 
immunity and ensuing hyper- inflammation might underlie the patho-
genesis of severe COVID- 19.18
T cells are central players in antiviral immunity. Effector T cells 
eliminate virus- infected cells, assist in innate antiviral response and 
support B cell responses, which culminate in the production of virus- 
specific antibodies.12 It has been convincingly shown that severe 
COVID- 19 is associated with reduced amounts of CD3+ T cells in pe-
ripheral blood and that the extent of T cell decrease correlates with 
disease severity.10,13,19,20 The reduction in peripheral T cells appears 
to be particularly prominent within the CD8+ T cell compartment, 
but it remains unclear if this is due to trafficking of CD8+ T cells into 
tissues with ongoing SARS- CoV- 2 replication, increased elimination 
of CD8+ T cells during COVID- 19, or pre- existing low levels of CD8+ 
T cells in individuals who experience severe disease.
Besides a quantitative reduction, qualitative perturbations of the T 
cell compartment have been observed. Several studies have reported 
an increased frequency of activated T cell phenotypes,21 as well as 
increased expression of surface markers typical of T cell exhaustion, 
such as PD- 1 and TIM- 3.19,22 While a number of reports have dealt 
with T cell reactivity to SARS- CoV- 2 proteins,23– 25 little is known about 
how functional responses of T cells are affected during COVID- 19.
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Patients with severe disease showed elevated interleukin- 7 and increased T cell pro-
liferation. Furthermore, patients sampled at late time points after symptom onset had 
higher T cell counts and improved antiviral T cell responses.
Conclusion: Our study suggests that severe COVID- 19 is characterized by extensive 
T cell dysfunction and T cell apoptosis, which is associated with signs of homeostatic 
T cell proliferation and T cell recovery.
K E Y W O R D S
COVID- 19, lymphopenia, SARS- CoV- 2, T cells
G R A P H I C A L  A B S T R A C T
In severe COVID- 19 T cell populations show perturbations, including loss of naïve T cells, CD4+ T cell skewing toward T follicular helper and 
cytotoxic phenotypes and expansion of activated and exhausted T cells. Apoptosis and migration contribute to the lymphopenia of severe 
disease, which is accompanied by Interleukin- 7 elevation. Functional responses to viral antigens are reduced in severe COVID- 19.
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To provide a detailed investigation of the peripheral T cell com-
partment, we performed mass cytometry, flow cytometry, targeted 
proteomics, and functional assays to phenotypically and functionally 
characterize the changes associated with symptomatic COVID- 19 
and relate them to disease severity. We observed peripheral T cell 
loss in both naïve and memory populations, especially among CD8+ 
F I G U R E  1  Characteristics of COVID- 19 patients and healthy subjects included in the cross- sectional study. (A) Number of subjects 
recruited into the study (left) and time since onset of symptoms at sampling (right). (B) Age distribution of controls and of patients grouped 
by disease severity subcategories. (C) Gender distribution of healthy subjects, patients with mild disease, and patients with severe disease. 
(D) t- SNE plots of normalized marker expression for up to 1,000 T cells from each sample analyzed by mass cytometry. Regions with high 
expression of specific markers appear red. (E) t- SNE plot of the T cells of our study colored by disease severity. Areas occupied prevalently 
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T cells, which was most prominent in severe disease. This was ac-
companied by increased T cell apoptosis, perturbations of the T cell 
compartment, and impaired T cell responses toward other viral an-
tigens. Furthermore, we observed stronger T cell responses in pa-
tients sampled at later time points after onset of symptoms, which, 
together with the increased Interleukin- 7 (IL- 7) serum concentra-
tions and evidence of substantial T cell proliferation, suggests a role 
for lymphopenia- induced proliferation in severe COVID- 19.
2  |  RESULTS
2.1  |  Characteristics of COVID- 19 patients and 
healthy subjects included in the cross- sectional study
To characterize the immune response associated with SARS- CoV- 2 
infection we conducted a prospective, observational, and cross- 
sectional study on symptomatic COVID- 19 patients recruited at 
hospitals in the Canton of Zurich, Switzerland. The included patients 
were stratified based on clinical disease severity at the time of sam-
pling (mild, n = 54; severe, n = 49); a group of healthy controls was 
included for comparison (n = 27) (Figure 1A). Patients were sampled 
at a single time point during their symptomatic phase (Figure 1A). 
Standard laboratory parameters and clinical characteristics of the in-
cluded patients are presented in Table 1. In agreement with previous 
studies,21,22 we observed that patient age was positively correlated 
with disease severity (Figure 1B) and that males were overrepre-
sented in the severe COVID- 19 subgroup (Figure 1C).
We performed a comprehensive T cell characterization making 
use of a mass cytometry panel (Table S1 and Figure S1A– C) in a sub-
set of patients (mild, n = 28; severe, n = 38, healthy, n = 22). These 
data are available at http://dx.doi.org/10.17632/ s84vd 72fsz.1. T 
cell- related markers were visualized on t- distributed Stochastic 
Neighbor Embedding (t- SNE) maps focusing on a subset of T cells 
from each sample, as identified based on a random forest classifi-
cation (Figure 1D, Figure S1D).26 By assessing the distribution of 
events on separate t- SNE maps for healthy controls, patients with 
mild disease and patients with severe disease, we observed differ-
ences between healthy donors and COVID- 19 patients (Figure 1E). 
Notably, cells from healthy individuals showed accumulation in an 
area of the t- SNE map enriched for CD45RA, whereas events from 
patients were more represented in areas enriched for CD45RO, 
CD57, and Granzyme B (Figure 1D– E).
2.2  |  Profound reduction in naïve and memory T 
cell populations in severe COVID- 19
We determined the frequencies of naïve, central memory, effec-
tor memory, and terminal effector memory expressing CD45RA 
(TEMRA) CD4+ and CD8+ T cell subsets by manual gating among all 
T cells in COVID- 19 patients and controls (Figure 2A,B, top panels). 
The frequency of the subsets within CD4+ or CD8+ cells is shown 
in stacked bar plots for individual patients (Figure 2A,B, bottom 
panels). As previously reported,21 patients with severe disease had 
decreased frequencies of naïve cells within the CD4+ and CD8+ T 
cell compartments compared to controls (Figure 2A– D). At the same 
time, the percentages of central memory CD4+and CD8+ T cells were 
increased in severe COVID- 19 (Figure 2C,D).
In order to investigate how the relative changes observed within 
the different T cell subsets related to absolute cell counts, we per-
formed flow cytometry of whole blood. By measuring absolute cell 
counts for CD4+ and CD8+ T cells we could calculate absolute num-
bers for the different T cell subpopulations within our mass cytom-
etry data set (Figure S2A). The marked reduction in naïve CD4+ and 
CD8+ T cells was confirmed by absolute counts and was especially 
pronounced for naïve CD8+ T cells (Figure 2C,D). In contrast, central 
memory and effector memory populations within the CD4+ T cell 
compartment also showed a reduction in COVID- 19 patients com-
pared to healthy controls (Figure 2C).
Absolute numbers of central memory CD8+ T cells, effector 
memory CD8+ T cells, and TEMRA CD8+ T cells were also reduced in 
patients with severe disease compared to controls (Figure 2D). Thus, 
in severe COVID- 19, naïve T cell reduction was not accompanied by 
memory T cell expansion but rather by a slight decrease of the mem-
ory compartment, especially among CD8+T cells. The impression of 
a relative increase in memory (especially central memory) popula-
tions was mainly created by the predominant reduction in naïve cells 
in the peripheral blood. Of note, the T cell reduction in peripheral 
blood was accompanied by strong T cell activation across all the 
main subsets (Figure S2B).
Patients with severe COVID- 19 in our cohort were older than 
patients with mild disease (Figure 1B), which could account for some 
differences in the distribution of T cell populations as previously 
proposed.27 Generally, both lymphopenia and naïve T cell reduction 
correlated with age (Figure S3A). Since age and clinical severity are 
strongly linked, some of the alterations within the T cell compart-
ment might be due to immunological aging. Upon stratification of 
patients according to age, we still detected differences between 
mild and severe COVID- 19 patients in terms of total and naïve T 
cells, although the CD8+ T cell reduction in patients above 60 years 
of age was not statistically significant (Figure S3B). The same was 
true when we stratified individuals according to gender (Figure S3C). 
In our healthy control group, we saw a correlation between age and 
CD8+ T cell decline (Figure S4A) while this was not the case for CD4+ 
cells. Conversely, CD4+ T cells were reduced in male individuals 
compared to females (Figure S4B).
2.3  |  Expansion of CD4+ T cells, with cytotoxic, 
activated and exhausted phenotypes in COVID- 19
We next investigated how the distribution of CD4+ T cell subpopula-
tions (Figure S5A) was altered during COVID- 19. We saw a significant 
increase in T follicular helper cells and T regulatory cells, as well as 
terminally differentiated, activated, and exhausted T cells (Figure 3A). 
    |  5ADAMO et Al.

















Grade at sampling – no. - 42 12 24 9 9 7
Maximal grade – no. - 38 10 23 10 11 11
Demographical characteristics
Age (median (IQR) [yrs]) 36.0 (30.0– 53.5) 42.00 (30.25– 57.75) 69.00 (58.0– 79.0)**
Gender (m/f) 13/14 28/26 31/18
Time since symptom onset (days) - 9.96 ± 8.73 18.55 ± 11.36*
Level of care at blood sampling time point
Outpatient – no. (%) - 35 (64.8) - 
Inpatient – no. (%) - 19 (35.2) 49 (100)*
Ward – no. (%) - 19 (35.2) 34 (69.4)
ICU – no. (%) - - 15 (30.6)
Outcome
Released/Recovered - 53 (98.1) 48 (98)
Deceased - 1 (1.9) 1 (2)
Laboratory characteristics
C- reactive protein
(mean ± SD, [mg/L])
1.20 ± 1.51 19.5 ± 40.09* 106.71 ± 99.04**
LDH(% of patients above reference value) 5% 16.7% 79.1%*
Hemoglobin
(mean ± SD, [g/L])
141.5 ± 11.77 139.68 ± 17.43 131.10 ± 15.38**
Absolute platelet count
(mean ± SD, [G/L])
254.68 ± 56.45 211.21 ± 63.39* 209.96 ± 109.21*
Total white blood cell count
(mean ± SD, [G/L])
5.86 ± 1.52 5.62 ± 2.50 7.14 ± 4.55
Monocytes
(mean ± SD, [G/L])
0.45 ± 0.14 0.51 ± 0.32 0.45 ± 0.34
Neutrophils
(mean ± SD, [G/L])
3.35 ± 1.15 3.42 ± 2.25 5.25 ± 3.34**
Eosinophils
(mean ± SD, [G/L])
0.15 ± 0.08 0.07 ± 0.08* 0.03 ± 0.07**
Basophils
(mean ± SD, [G/L])
0.04 ± 0.02 0.02 ± 0.02* 0.01 ± 0.02**
Lymphocytes
(mean ± SD, [G/L])
1.85 ± 0.65 1.56 ± 0.72 0.82 ± 0.45**
CD3- CD56bright CD16dim NK cells
(mean ± SD, [cells/µL])
10.5 ± 5.39 9.17 ± 5.63 6.14 ± 5.09**
CD3- CD56dim CD16bright NK cells
(mean ± SD, [cells/µL])
204.69 ± 110.88 191.98 ± 139.98 152.14 ± 99.75
Comorbidities
Hypertension – no. (%) 4 (14.8) 12 (22.2) 29 (59.2)*
Diabetes – no. (%) 2 (7.4) 7 (13) 15 (30.6)*
Heart disease – no. (%) 1 (3.7) 6 (11.1) 22 (44.9)*
Cerebrovascular disease – no. (%) - 2 (3.7) 5 (10.2)
Lung disease – no. (%) 1 (3.7) 6 (11.1) 7 (14.3)
Kidney disease – no. (%) - 9 (16.7) 14 (28.6)*
(Continues)
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Interestingly, a population of Granzyme B+ terminally differentiated 
(CD28−) cells, compatible with cytotoxic CD4+ T cells, that was ab-
sent in healthy controls was strongly increased in COVID- 19. This 
population likely corresponds to the one identified at the transcrip-
tional level by others.28 Given the profound lymphopenia of severe 
COVID- 19 patients (Figures S2A,S6A), we sought to relate our find-
ings to absolute counts. This was especially important because a 
disproportionate reduction in specific populations could create the 
illusion of an expansion of other populations as observed for naïve 
and memory cells. By investigating absolute counts, we saw that the 
increased percentage of T follicular helper cells reflected a real ex-
pansion of this population in peripheral blood, likely contributing to 
the robust antibody responses observed in COVID- 19,12 while Th1 
cell counts were reduced. T regulatory cells were strongly altered 
in terms of frequency but not in absolute counts (Figure 3B), per-
haps reflecting a shift in the global distribution of CD4+ T cell subsets 
rather than T regulatory cell proliferation. Expansion of CD4+ T cells 
with a cytotoxic phenotype, terminally differentiated and exhausted 
cells was also confirmed by absolute counts (Figure 3B).
In order to visualize the most prominent changes within the CD4+ 
compartment we calculated the fold change of absolute counts for 
the described T cell populations between mild and severe COVID- 19 
as well as healthy controls (Figure 3C). Indeed, we observed that the 
most prominent changes in patients with severe COVID- 19 com-
pared to healthy controls was the increase in cytotoxic CD4+ T cells, 
as well as the increase in terminally differentiated and exhausted 
cells. We next analyzed populations within the CD8+ compartment 
(Figure S5B) and observed an increase of activated and exhausted 
CD8+ T cells in terms of frequency (Figure 3D) and absolute counts 
(Figure 3E). CD8+ T cells with a cytotoxic phenotype (Granzyme B+, 
CD28−) were increased in percentage but not in absolute number 
(Figure 3D– F). Among CD8+ cells, the most prominent change ob-
served was the increase in exhausted T cells, which also showed 
a strong difference between mild and severe patients (Figure 3F). 
PhenoGraph unsupervised clustering of T cell populations revealed 
a similar picture (Figure S7A– B).
2.4  |  T cell apoptosis and indirect signs of T cell 
migration in severe COVID- 19
We next investigated apoptosis and cell migration as possible 
mechanisms contributing to peripheral T cell loss in patients with 

















Malignancy – no. (%) 1 (3.7) 2 (3.7) 5 (10.2)
Systemic Immunosuppression – no. (%) - 3 (5.6) 5 (10.2)
Treatment at sampling
Hydroxychloroquine – no. (%) - 2 (3.7) 19 (38.8)*
Remdesivir– no. (%) - 3 (5.6) 10 (20.4)*
Glucocorticoids – no. (%)c  - - 5 (10.2)*
Lopinavir- Ritonavir– no. (%) - - 1 (2)
Tocilizumab – no. (%) - - 3 (6.1)
Glucocorticoids pre- COVID – no. (%) 2 (3.7) 5 (10.2)
Mycophenolate Mofetil– no. (%) - 1 (1.9) - 
Calcineurin Inhibitors – no. (%) - 1 (1.9) 1 (2)
Azathioprine – no. (%) - - 2 (4.1)
Leflunomide – no. (%) - 1 (1.9) - 
Mesalazine– no. (%) - 1 (1.9) - 
Methotrexate – no. (%) - 1 (1.9) - 
Rituximab – no. (%) - 1 (1.9) - 
Note: Mann- Whitney- Wilcoxon test was used to test for differences between continuous variables adjusted for multiple testing using the Holm 
method. * Indicates significance (p- value threshold <.05) compared to the healthy, ** in the severe indicates significance in comparison to the healthy 
and the mild. Categorical variables were compared using Chi- square test, * indicates significance (p- value threshold <.05) overall.
Abbreviations: ARDS, acute respiratory distress syndrome; ICU, intensive care unit; IQR, interquartile range; LDH, Lactate Dehydrogenase.
aCOVID- 19 disease severity at the time of blood sample collection. Mild illness and pneumonia are considered mild COVID- 19 disease and severe 
pneumonia as well as any grade of ARDS are considered severe COVID- 19 disease.
bCOVID- 19 grade according to WHO guidelines, recorded at sampling and prospectively followed until recovery.
cGlucocorticoids initiated as part of the COVID- 19 treatment.
TA B L E  1  (Continued)
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in severe COVID- 19 including cytokine signaling, direct interaction 
of the virus with T cells via CD26 or CD147 and elevated plasma Fas 
ligand levels as described for SARS- CoV.29,30
Excessive pro- inflammatory cytokine signaling, especially medi-
ated by TNF- α, can directly lead to T cell apoptosis.31 As TNF- α levels 
were considerably elevated in our cohort (Figure S8A) in agreement 
F I G U R E  2  Naïve and memory T cells are profoundly reduced in severe COVID- 19. (A) Gating strategy for naive and memory populations 
as shown on representative mass cytometry plots for CD4+ (top) and stacked histograms with frequencies of regulatory T cells and naive and 
memory (central memory, effector memory) CD4+ T cells for healthy controls and mild and severe disease categories (bottom). (B) Gating 
strategy for naive and memory populations as shown on representative mass cytometry plots for CD8+ (top) and stacked histograms with 
frequencies of naive and memory (central memory, effector memory, TEMRA) CD8+ T cells for healthy controls and mild and severe disease 
categories (bottom). (C) Percentages (top) and absolute counts (bottom) of CD4+ T cell subsets in healthy subjects and patients with mild 
and severe COVID- 19 shown as individual dots. Box plots display median and interquartile ranges. Indicated p values were calculated with 
a Mann- Whitney- Wilcoxon test and adjusted for multiple comparisons with the Holm method. (D) Percentages (top) and absolute counts 
(bottom) of CD8+ T cell subsets in healthy subjects and patients with mild and severe COVID- 19 shown as individual dots. Boxplot display 
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8  |    ADAMO et Al.
with previous reports,17,32 we hypothesized that apoptosis could 
drive T cell loss during severe COVID- 19 disease. We thus deter-
mined the percentage of apoptotic cells among the main CD4+ and 
CD8+ T cell subsets. We defined apoptotic cells as cells positive for 
cleaved caspase- 3 and/or cleaved PARP, as cleavage of both of these 
substrates occurs during apoptosis and positivity for the cleaved 
form of these proteins can be used as evidence of an apoptotic state.
Indeed, we observed significant increases in the percentages of 
apoptotic cells among central and effector memory CD4+ T cells, as 
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TEMRA CD8+ T cells (Figure 4A). Among CD8+ T cells, the extent 
of apoptosis was greater in samples from patients with severe as 
compared to mild COVID- 19 (Figure 4A). Even within the group with 
mild disease, the extent of T cell apoptosis was strongly associated 
with symptom severity in the CD8 subset as shown by increased 
apoptosis in patients with mild pneumonia (Figure 4B). Increased T 
cell apoptosis could thus contribute to the lymphopenia that is a hall-
mark of severe COVID- 19.
T cell reduction in peripheral blood can also be a consequence 
of T cell migration to tissues and lymphocyte accumulation in the 
lungs during COVID- 19 has been reported by some 33,34 but not by 
others.35,36 We therefore looked for indirect signs of T cell migration 
in the peripheral blood of COVID- 19 patients. T cell migration into 
inflamed lung parenchyma is primarily mediated by CXCR3 signal-
ing,37,38 so we investigated the level of CXCR3 ligands in the serum 
of COVID- 19 patients. CXCR3 ligands CXCL9, CXCL10, and CXCL11 
were significantly increased in sera from COVID- 19 patients, es-
pecially in sera from patients with severe disease (Figure 4C). 
Furthermore, IFN- γ, a potent inducer of CXCR3 ligands,39 was mark-
edly elevated (Figure 4C and Figure S8B). We also observed a very 
strong reduction in CXCR3 expression in all the main T cell subsets 
with the exception of naïve CD4+ T cells in COVID- 19 patients 
(Figure 4D and Figure S8C). Reduced CXCR3 expression on MAIT 
cells and CD8+ T cells has previously been reported,40 whereas re-
duced CXCR3 levels on memory CD4+ populations have been as-
sociated with a negative prognosis.41 CXCR3 abundance inversely 
correlated with levels of CXCL9, CXCL10, CXCL11, and IFN- γ, and 
was positively correlated with CD3+, CD4+, and CD8+ T cell frequen-
cies (Figure 4E). The frequency of apoptosis in CD4+ and CD8+ T cell 
populations also seemed to inversely correlate with absolute T cell 
numbers (Figure 4E). Taken together, our data suggest that both mi-
gration and apoptosis might contribute to T cell lymphopenia.
2.5  |  Reduced in vitro T cell function in patients 
with COVID- 19
We next investigated whether the observed changes within the 
T cell compartment associated with COVID- 19 had an impact 
on T cell function. We took advantage of our clinically validated 
flow cytometric assay for specific cell- mediated immune re-
sponses in activated whole blood (FASCIA).42,43 This routine 
assay measures the ability of peripheral T cells in whole blood to 
form blasts in response to mitogens, super- antigens, and a selec-
tion of common viral antigens. In patients with severe COVID- 19, 
we observed reduced blast formation upon stimulation with ad-
enovirus, Cytomegalovirus (CMV), Herpes simplex virus 1 (HSV1), 
Herpes simplex virus 2 (HSV2) and Varicella Zoster Virus (VZV) 
in COVID- 19 as compared to healthy controls or patients with 
mild disease (Figure 5A). The same tendency was not observed 
when blood cells were incubated with pokeweed mitogen or 
Staphylococcal super- antigens (SEA/SEB), but we did observe a 
reduction blast formation upon stimulation with concavalin A 
(Figure 5A). The discrepancy between different mitogens is diffi-
cult to interpret, as pokeweed mitogen and concavalin A are both 
plant lectins, known to induce mitosis in T cells, but their exact 
mechanism of action is not known. We next investigated whether 
the reduction in antiviral T cell responses was associated with the 
time between sampling and symptom onset in our cross- sectional 
study. Interestingly, we observed a positive correlation between 
blast formation and time after symptom onset upon stimulation 
with HSV1, HSV2, and adenovirus (Figure 5B and Figure S9A). A 
trend toward a positive correlation was also observed for CMV and 
VZV stimulation of samples from patients with severe COVID- 19, 
but not for stimulation with mitogens or super- antigens (Figure 5B 
and Figure S9A). Taken together, these data suggest that antiviral T 
cell responses are impaired in patients with severe COVID- 19 and 
that these responses tend to improve in patients sampled at later 
time points from symptom onset.
Reduced blast formation upon stimulation with specific viral anti-
gens is likely mediated by a combination of factors, but reduced fre-
quency of virus- specific memory T cells is likely to play a central role. 
In support of this, we found that blast formation positively correlated 
with absolute peripheral CD4+ and CD8+ T cell counts (Figure S9B,C). 
We therefore hypothesized that the improvement of T cell function 
at later stages of the infection might be partially due to reconstitu-
tion of the peripheral T cell compartment. Indeed, we observed higher 
absolute peripheral T cell counts in samples from patients with se-
vere COVID- 19 obtained at later time points after symptom onset as 
compared to samples obtained earlier in the disease course, especially 
F I G U R E  3  Several T cell subsets are increased in mild and severe COVID- 19. (A) Percentages of CD4+ T cell subsets identified with 
mass cytometry in healthy subjects and patients with mild and severe COVID- 19 shown as individual dots. Box plots display median and 
interquartile ranges (shown are percentages of total CD4+). Indicated p values were calculated with a Mann- Whitney- Wilcoxon test and 
adjusted for multiple comparisons with the Holm method. (B) Absolute counts of CD4+ T cell subsets identified with mass cytometry in 
healthy subjects and patients with mild and severe COVID- 19 shown as individual dots. Box plots display median and interquartile ranges. 
Statistical testing was performed as in (A). (C) Log2 fold change of absolute counts of CD4+ T cell subsets for mild COVID- 19 compared to 
healthy (mild vs. healthy), severe COVID- 19 compared to healthy (severe vs. healthy) and severe COVID- 19 compared to mild COVID- 19 
(severe vs. mild) is shown as a heatmap. (D) Percentages of CD8+ T cell subsets identified with mass cytometry in healthy subjects and 
patients with mild and severe COVID- 19 shown as individual dots. Box plots display median and interquartile ranges (shown are percentages 
of total CD8+). Statistical testing was performed as in (A). (E) Absolute counts of CD8+ T cell subsets identified with mass cytometry in 
healthy subjects and patients with mild and severe COVID- 19 shown as individual dots. Box plots display median and interquartile ranges. 
Statistical testing was performed as in (A). (F) Log2 fold change of absolute counts of CD8+ T cell subsets for mild COVID- 19 compared to 
healthy (mild vs. healthy), severe COVID- 19 compared to healthy (severe vs. healthy) and severe COVID- 19 compared to mild COVID- 19 
(severe vs. mild) is shown as a heatmap
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F I G U R E  4  Severe COVID- 19 is associated with lymphopenia, apoptosis and phenotypic changes of T cells. (A) Percentages of apoptotic 
(cleaved- PARP/cleaved Caspase 3+) cells among CD4+ T cell subsets and CD8+ T cell identified with mass cytometry in healthy subjects and 
patients with mild and severe COVID- 19 patients shown as individual dots. Box plots display median and interquartile ranges. Indicated p 
values were calculated with a Mann– Whitney– Wilcoxon test and adjusted for multiple comparisons with the Holm method. (B) Percentages 
of apoptotic (cleaved- PARP/cleaved Caspase 3+) cells among CD4+ T cells and CD8+ T cell identified with mass cytometry in patients with 
mild illness vs. mild pneumonia. Indicated p values were calculated with a Mann– Whitney– Wilcoxon test. (C) CXCL9, CXCL10, CXCL11, 
and IFN- γ serum levels in healthy subjects and patients with mild and severe COVID- 19 measured with an Olink proximity extension assay 
shown as individual dots. Box plots display median and interquartile ranges. Statistical testing was performed as in (A). (D) CXCR3 mean ion 
count (MIC) of CD4+ T cell subsets (top) and CD8+ T cell subsets (bottom) in healthy subjects and patients with mild and severe COVID- 19. 
Statistical testing was performed as in (A). (E) Pearson correlation analyses among CXCR3, CXCL9, CXCL10, CXCL11, and IFN- γ levels, 
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for CD8+T cells (Figure 5C). To explore whether T cell reconstitution 
was a potential mechanism, we investigated T cell proliferation in 
the different T cell populations. We could indeed observe increased 
frequencies of proliferating (Ki- 67+) in multiple subsets of CD4+ and 
CD8+ T cells in COVID- 19 patients, especially in patients with severe 
disease (Figure 5D and Figure S10A– B).
Given the extent of the lymphopenia in severe COVID- 19 we 
hypothesized that lymphopenia- induced proliferation might play a 
role. IL- 7 is known to be a critical homeostatic factor for T cells, and 
since IL- 7 production by stromal cells is relatively constant,44,45 IL- 7 
serum levels are mainly regulated by its consumption by lympho-
cytes. In patients with severe disease, we observed higher serum 
IL- 7 levels compared to those with mild disease and healthy controls 
(Figure 5E), in agreement with a previous report.46 Furthermore, 
IL- 7 levels inversely correlated with the total number of CD3+, CD4+ 
and CD8+ T cells (Figure 5F). Taken together, these findings suggest 
that the lymphopenia in severe COVID- 19 could result in a systemic 
IL- 7 elevation, which in turn might contribute to the observed T cell 
proliferation.
3  |  DISCUSSION
T cell lymphopenia and perturbations of T cell homeostasis are very 
prominent features of severe COVID- 19, but their pathogenesis has 
not yet been fully elucidated. A better understanding of the T cell al-
terations occurring in severe COVID- 19 can provide insight into im-
portant disease mechanisms and inform therapeutic strategies. We 
performed detailed investigations of relative and absolute changes 
to the peripheral T cell compartment in our well characterized 
COVID- 19 cohort. Our analysis revealed marked T cell loss across 
naïve and memory cells in the CD4+ and CD8+ T cell compartment 
in patients with COVID- 19 compared to healthy controls. However, 
certain T cell populations such as cytotoxic, activated and exhausted 
cells were expanded, especially in severe COVID- 19. We were able 
to identify apoptosis as a possible mechanism driving the lympho-
penia and observed signs of T cell reconstitution at later time points 
from symptom onset.
The occurrence of peripheral lymphopenia has been described 
in several human acute respiratory viral infections.47,48 In severe 
COVID- 19, the extent of lymphopenia is closely linked to disease se-
verity and mortality.32 Since disease severity in COVID- 19 is strongly 
associated with biological age, age- associated decline in lymphocyte 
counts could in part account for the observed lymphopenia. A recent 
study, which showed a strong correlation between T cell lympho-
penia, diminished SARS- CoV- 2- specific T cell responses and severe 
disease also suggested an association between age and decline in 
the fraction of naïve CD8+ T cells.18 Investigating the effect of age 
in our patient cohort poses a challenge, as this is strongly linked to 
disease severity. In our healthy control group, however, we saw a 
correlation between age and CD8+ T cell decline, while this was not 
the case for CD4+ cells. Despite association with disease severity 
and male gender, we did not observe CD8+ T cell reduction when 
comparing males to females among healthy controls, but saw a mod-
est reduction of CD4+ T cells. Given the limited number of subjects, 
these data must be interpreted with caution, but it is conceivable 
that age and gender account for pre- existing alterations of the T cell 
compartment that influence the course of COVID- 19 disease.
Within the T cell compartments, we saw a prevalent reduction of 
naïve T cells, which resulted in increased memory subsets percent-
ages despite the slight contraction in absolute numbers. Whether 
the loss of naïve populations can be explained by the acquisition of a 
memory phenotype by virus specific cells or in an antigen indepen-
dent way remains to be seen.
Another potential explanation for the loss of naïve cells might 
be selective or preferential death of these subsets. In this study we 
observed extensive T cell apoptosis in COVID- 19, especially among 
CD8+ T cells, suggesting that apoptosis could be a central mecha-
nism in the immunopathology of severe COVID- 19. Apoptosis could 
be caused by the inflammatory microenvironment generated by 
SARS- CoV- 2, although a direct interaction of the virus with T cells 
via CD147 or CD26 or perhaps even T cell infection cannot be ex-
cluded. In our study, we could not identify a temporal component 
to the increased apoptosis, but we observed signs of T cell recovery 
starting at day 20, suggesting that apoptosis might occur relatively 
early in the disease course.
Lymphocyte redistribution, that is, migration to inflamed tis-
sues, can also be a cause of apparent peripheral lymphopenia. In 
our study, we found elevated amounts of CXCL9, CXCL10, and 
CXCL11. These chemokines are known to be produced in response 
to viral infection and are mainly responsible for T cell and NK cell 
recruitment to the site of infection. Together with the reduced 
surface expression of CXCR3, our data could suggest migration of 
cells expressing higher levels of CXCR3 to the tissue, accounting 
for their disappearance from the peripheral blood, although down-
regulation of CXCR3 in response to its ligands or antigen activation 
cannot be excluded.
Based on our data, the changes in T cell populations in COVID- 19 
might be due to T cell apoptosis, migration, proliferation or differ-
entiation. For example, expansion of T follicular helper cells might 
result from a combination of differentiation and proliferation, while 
contraction of Th1 could depend on migration and apoptosis in this 
population. Although migration and apoptosis are both possible 
mechanisms, higher T cell counts in the lung do not seem to cor-
relate with disease severity.49,50 Furthermore, IL- 7 elevation in se-
vere disease likely results from global T cell loss, rather than T cell 
re- distribution or activation- induced downregulation of the IL- 7 
receptor α subunit.51,52 Taken together, these findings suggest that 
apoptosis might be central to the development of lymphopenia in 
severe COVID- 19.
When investigating the T cell function in COVID- 19, we found 
reduced T cell responses to several viral antigens in severe disease. 
The most likely explanation for this finding is a reduction in the pre-
cursor frequency of memory cells specific for common antigens. A 
similar effect has recently been described for B cells in measles,53,54 
where it has been linked to direct B cell infection and cell death. In 
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the measle studies, alteration of the B cell repertoire can last for 
years, whereas we observed an improvement of T cell function in 
patients sampled later in the disease courses (day 30– 40), which 
occurred in parallel with recovery of T cell counts. This dynamic was 
present only in patients with severe disease, probably because the 
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which could in turn trigger lymphopenia- induced IL- 7- mediated ho-
meostatic proliferation, as reported for other viral infections.55
Understanding the immunological mechanisms underlying severe 
COVID- 19 disease is necessary for risk stratification and the development 
of interventional therapies, including those aimed at lymphopenia, 56 and 
protective vaccines. Our study reveals perturbations within CD4+and 
CD8+ T cell compartments, confirming the association between severe 
disease, age and T cell lymphopenia, and showing that the lymphopenia 
is likely partially mediated by a COVID- 19 associated apoptotic T cell loss. 
The observed increased T cell apoptosis in severe disease is closely as-
sociated with a highly inflammatory innate immune response. Thus, our 
study highlights the potential of therapies targeting T cell dysregulation 
and excessive inflammation in possibly limiting the observed extensive T 
cell loss associated with severe COVID- 19. One promising immunomod-
ulatory therapeutic approach is the use of JAK inhibitors in patients with 
severe COIVD- 19. A recent randomized controlled trial with Baricitinib 
57 showed promising effects, especially in patients receiving high- flow 
oxygen or non- invasive ventilation. Further studies investigating how im-
munomodulatory therapies such as JAK- inhibitors affect the innate and 
adaptive immune responses in severe COVID- 19 are needed.
4  |  METHODS
4.1  |  Subjects characteristics
Patients aged 18 years and older with symptomatic, RT- qPCR con-
firmed SARS- CoV- 2 infection were recruited at four different hos-
pitals in the Canton of Zurich, Switzerland, between April 2 and 
August 19 2020. Both hospitalized patients and outpatients were 
recruited into the study and all participants gave written informed 
consent. The study was approved by the Cantonal Ethics Committee 
of Zurich (BASEC 2016– 01440). A more detailed description of the 
cohort is provided in the Appendix S1.
4.2  |  Flow cytometry
For quantification of the main T cell subsets, blood samples were 
processed in the accredited routine immunology laboratory at 
University Hospital Zurich. Flow cytometry staining, assessment 
and analysis was done as established,58,59 using the reagents and 
methodology detailed in the Appendix S1.
4.3  |  Mass cytometry analysis
Samples were pre- processed as described in the Appendix S1 
and mass cytometry analysis was performed as previously 
described.17,60– 67 A detailed description of the procedure is provided 
in the Appendix S1.
4.4  |  Flow cytometric assay for specific cell- 
mediated immune responses in whole blood
Venous blood collected in sodium heparin tubes was diluted 
with RPMI 1,640 medium supplemented with 10% FBS, 100 IU/
mL penicillin and 100 IU/mL streptomycin (all from Gibco). Blood 
cells were stimulated with pokeweed mitogen, Concanavalin A, 
Staphylococcus enterotoxins A and B, or antigens from varicella 
zoster virus (VZV), adenovirus, cytomegalovirus (CMV), herpes 
simplex virus 1 (HSV1), or herpes simplex virus 2 (HSV2) or left un-
stimulated for 7 days. Cells were then stained with live/dead fix-
able Aqua stain (Thermo Fisher, catalog number L34957) and with 
Cyto- stat tetrachrome (containing FITC anti- CD45, PECy5 anti-
 CD3, PE anti- CD4, and ECD anti- CD8; Beckman Coulter, catalog 
number 660713). Data were acquired on a Navios flow cytometer 
and analyzed with Kaluza analysis software. Net stimulation was 
calculated by subtracting the percentage of CD3+ blasts over all 
lymphocytes in the unstimulated sample from their counterparts 
in stimulated samples.
4.5  |  Cytokine measurements
Serum was collected in BD vacutainer clot activator tubes (Becton 
Dickinson). The samples were processed in an accredited immunol-
ogy laboratory at the Department of Immunology of University 
Hospital Zurich. IFN- γ and TNF- α were quantified using an ELISA 
(R&D Systems), as previously established.68
4.6  |  Proteomics analyses
Heat- inactivated plasma samples were analyzed using the Olink® 
Proteomics 92- plex inflammation immunoassay. A brief description 
of the method is provided in the Appendix S1.
F I G U R E  5  Reduced T cell responses toward viral antigens and signs of T cell recovery are evident in severe COVID- 19. (A) Net stimulation 
of CD3+ T cells observed in the presence of mitogens, super antigens and viral antigens shown as individual dots. Box plots display median 
and interquartile ranges. Indicated p values were calculated with a Mann– Whitney– Wilcoxon test and adjusted for multiple comparisons 
with the Holm method. (B) Linear modeling of blast formation as a function of time after symptom onset in mild and severe COVID- 19. (C) 
CD3+, CD4+, and CD8+ T cell counts are a function of time after symptom onset in patients with mild and severe COVID- 19 as shown by 
a linear model. Counts for healthy subjects are shown for reference but were not included in the model. (D) Percentages of proliferating 
(Ki- 67+) cells among CD4+ T cell subsets (top) and CD8+ T cell subsets (bottom) identified with mass cytometry in healthy subjects and 
patients with mild and severe COVID- 19 shown as individual dots. Box plots display median and interquartile ranges. Statistical testing was 
performed as in (A). (E) IL- 7 serum levels in healthy subjects and patients with mild and severe COVID- 19 measured with the Olink proximity 
extension assay shown as individual dots. Box plots display median and interquartile range. Statistical testing was performed as in (A). (F) IL- 7 
serum level is a function of CD4+ T cells, and CD8+ T cells as shown by a linear model
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